Comparison of Tumor Related Signaling Pathways with Known Compounds to Determine Potential Agents for Lung Adenocarcinoma

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2018 Jun 6

PMID 29870138

Citations 3

Authors

Song Xu

Renwang Liu

Yurong Da

Affiliations

Soon will be listed here.

Abstract

Background: This study compared tumor-related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma (LUAD) treatment.

Methods: Kyoto Encyclopedia of Genes and Genomes signaling pathway analyses were performed based on LUAD differentially expressed genes from The Cancer Genome Atlas (TCGA) project and genotype-tissue expression controls. These results were compared to various known compounds using the Connectivity Mapping dataset. The clinical significance of the hub genes identified by overlapping pathway enrichment analysis was further investigated using data mining from multiple sources. A drug-pathway network for LUAD was constructed, and molecular docking was carried out.

Results: After the integration of 57 LUAD-related pathways and 35 pathways affected by small molecules, five overlapping pathways were revealed. Among these five pathways, the p53 signaling pathway was the most significant, with CCNB1, CCNB2, CDK1, CDKN2A, and CHEK1 being identified as hub genes. The p53 signaling pathway is implicated as a risk factor for LUAD tumorigenesis and survival. A total of 88 molecules significantly inhibiting the five LUAD-related oncogenic pathways were involved in the LUAD drug-pathway network. Daunorubicin, mycophenolic acid, and pyrvinium could potentially target the hub gene CHEK1 directly.

Conclusion: Our study highlights the critical pathways that should be targeted in the search for potential LUAD treatments, most importantly, the p53 signaling pathway. Some compounds, such as ciclopirox and AG-028671, may have potential roles for LUAD treatment but require further experimental verification.

Citing Articles

Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.

Rabby M, Islam M, Kumar S, Maniruzzaman M, Hasan M, Tomioka Y PLoS One. 2025; 20(2):e0317296.

PMID: 40014586 PMC: 11867339. DOI: 10.1371/journal.pone.0317296.

Ciclopirox Olamine Exerts Tumor-Suppressor Effects Topoisomerase II Alpha in Lung Adenocarcinoma.

Yin J, Che G, Jiang K, Zhou Z, Wu L, Xu M Front Oncol. 2022; 12:791916.

PMID: 35251970 PMC: 8894728. DOI: 10.3389/fonc.2022.791916.

High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma.

Chang S, Zhu Y, Xi Y, Gao F, Lu J, Dong L Int J Gen Med. 2021; 14:6961-6974.

PMID: 34707388 PMC: 8542575. DOI: 10.2147/IJGM.S329482.

Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers.

Yang J, Mu X, Wang Y, Zhu D, Zhang J, Liang C Front Oncol. 2018; 8:520.

PMID: 30524957 PMC: 6256243. DOI: 10.3389/fonc.2018.00520.

References

Chen G, Umelo I, Lv S, Teugels E, Fostier K, Kronenberger P . miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 2013; 8(3):e60317. PMC: 3608584. DOI: 10.1371/journal.pone.0060317. View

Zhao M, Liu Y, Liu R, Qi J, Hou Y, Chang J . Upregulation of IL-11, an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2018; 45(6):2213-2224. DOI: 10.1159/000488166. View

Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G . A pathology atlas of the human cancer transcriptome. Science. 2017; 357(6352). DOI: 10.1126/science.aan2507. View

Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A . SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013; 8(9):e74250. PMC: 3774754. DOI: 10.1371/journal.pone.0074250. View

Feng Y, Zhou J, Jiang Y . Resveratrol in lung cancer- a systematic review. J BUON. 2016; 21(4):950-953. View

Chen G, Noor A, Kronenberger P, Teugels E, Umelo I, De Greve J . Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013; 8(3):e59708. PMC: 3601073. DOI: 10.1371/journal.pone.0059708. View

Stankevicius V, Vasauskas G, Bulotiene D, Butkyte S, Jarmalaite S, Rotomskis R . Gene and miRNA expression signature of Lewis lung carcinoma LLC1 cells in extracellular matrix enriched microenvironment. BMC Cancer. 2016; 16(1):789. PMC: 5057255. DOI: 10.1186/s12885-016-2825-9. View

He R, Li X, Liang L, Xie Y, Luo D, Ma J . The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model. BMC Cancer. 2017; 17(1):655. PMC: 5606087. DOI: 10.1186/s12885-017-3646-1. View

Jaravine V, Mosch A, Raffegerst S, Schendel D, Frishman D . Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues. BMC Cancer. 2017; 17(1):892. PMC: 5745885. DOI: 10.1186/s12885-017-3854-8. View

10.

Spain L, Diem S, Larkin J . Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44:51-60. DOI: 10.1016/j.ctrv.2016.02.001. View

11.

Fukuda M, Okumura M, Iwakiri T, Arimori K, Honda T, Kobayashi K . Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. Thorac Cancer. 2017; 9(1):51-58. PMC: 5754284. DOI: 10.1111/1759-7714.12535. View

12.

Wang X, Li G, Luo Q, Xie J, Gan C . Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. Cancer Cell Int. 2018; 18:27. PMC: 5824544. DOI: 10.1186/s12935-018-0513-3. View

13.

Feng H, Zhao Y, Zhang J, Zhang J, Jiang P, Li B . Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer. Oncol Lett. 2018; 15(2):2661-2668. PMC: 5777290. DOI: 10.3892/ol.2017.7591. View

14.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

15.

Yuan B, Ji W, Xia H, Li J . Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Mol Med Rep. 2018; 17(3):4291-4298. PMC: 5802202. DOI: 10.3892/mmr.2018.8418. View

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

17.

de Oliveira V, Lisboa da Motta L, De Bastiani M, Lopes F, Muller C, Gabiatti B . In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells. Tumour Biol. 2016; 37(8):10775-84. DOI: 10.1007/s13277-016-4973-6. View

18.

Chen Y, Li C, Pan Y, Han S, Feng B, Gao Y . The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment. Cell Physiol Biochem. 2016; 38(6):2194-206. DOI: 10.1159/000445575. View

19.

Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T . Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer. 2017; 17(1):377. PMC: 5446686. DOI: 10.1186/s12885-017-3353-y. View

20.

Namani A, Rahaman M, Chen M, Tang X . Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. BMC Cancer. 2018; 18(1):46. PMC: 5756380. DOI: 10.1186/s12885-017-3907-z. View